BAIT

CEBPA

C/ebpalpha, CBF-A, Cebp
CCAAT/enhancer binding protein (C/EBP), alpha
GO Process (29)
GO Function (16)
GO Component (6)
Mus musculus
PREY

VCP

3110001E05, CDC48, p97, p97/VCP, RP23-124L1.5
valosin containing protein
GO Process (19)
GO Function (13)
GO Component (15)
Mus musculus

Affinity Capture-MS

An interaction is inferred when a bait protein is affinity captured from cell extracts by either polyclonal antibody or epitope tag and the associated interaction partner is identified by mass spectrometric methods.

Publication

Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.

Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KV, Schoenegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G

The CEBPA gene is mutated in 9% of patients with acute myeloid leukemia (AML). Selective expression of a short (30-kDa) CCAAT-enhancer binding protein-α (C/EBPα) translational isoform, termed p30, represents the most common type of CEBPA mutation in AML. The molecular mechanisms underlying p30-mediated transformation remain incompletely understood. We show that C/EBPα p30, but not the normal p42 isoform, preferentially interacts ... [more]

Nat. Chem. Biol. Aug. 01, 2015; 11(8);571-8 [Pubmed: 26167872]

Throughput

  • High Throughput

Additional Notes

  • p30 isoform

Curated By

  • BioGRID